Your browser doesn't support javascript.
loading
Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
Amin Addetia; Young-Jun Park; Tyler Starr; Allison J Greaney; Kaitlin Sprouse; John E Bowen; Sasha W Tiles; Wesley C Van Voorhis; Jesse D Bloom; Davide Corti; Alexandra C Walls; David Veesler.
Afiliação
  • Amin Addetia; University of Washington
  • Young-Jun Park; University of Washington
  • Tyler Starr; Fred Hutchinson Cancer Research Center
  • Allison J Greaney; Fred Hutchinson Cancer Research Center
  • Kaitlin Sprouse; University of Washington
  • John E Bowen; University of Washington
  • Sasha W Tiles; University of Washington
  • Wesley C Van Voorhis; University of Washington
  • Jesse D Bloom; Fred Hutchinson Cancer Research Center
  • Davide Corti; Humabs Biomed SA
  • Alexandra C Walls; University of Washington
  • David Veesler; University of Washington
Preprint em Inglês | bioRxiv | ID: ppbiorxiv-477288
ABSTRACT
The SARS-CoV-2 receptor-binding domain (RBD) E406W mutation abrogates neutralization mediated by the REGEN-CoV therapeutic monoclonal antibody (mAb) COVID-19 cocktail and the cilgavimab (AZD1061) mAb. Here, we show that this residue substitution remodels the ACE2-binding site allosterically, thereby dampening receptor recognition severely and altering the epitopes recognized by these three mAbs. Although vaccine-elicited neutralizing antibody titers are decreased similarly against the E406 mutant and the Delta or Epsilon variants, broadly neutralizing sarbecovirus mAbs, including a clinical mAb, inhibit the E406W spike mutant.
Licença
cc_by_nc_nd
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: bioRxiv Tipo de estudo: Estudo prognóstico Idioma: Inglês Ano de publicação: 2022 Tipo de documento: Preprint
...